2015 APHA Annual Meeting & Expo

Home Events & Meetings Annual Meeting Schedule & Program

Recorded Annual Meeting Presentations (RAMP) are now available for purchase.
Only $90 for presenters, $140 for registered attendees and $200 for non-attendees.

Online Program

337953
Ebola Treatment Center Inventory of Capabilities: Regional Centers


Monday, November 2, 2015

Jocelyn Herstein, MPH, College of Public Health, Department of Environmental, Agricultural, and Occupational Health, University of Nebraska Medical Center, Omaha, NE
Katelyn Jelden, MPH, College of Medicine, University of Nebraska Medical Center, Omaha, NE
Colleen Kraft, MD, Department of Pathology at Emory University School of Medicine, Emory, Atlanta, GA
Paul Biddinger, MD, FACEP, Massachusetts General Hospital, Boston, MA
Lisa Saiman, MD, MPH, Department of Pediatrics: Division of Pediatric Infectious Diseases, Columbia University, New York, NY
Shawn Gibbs, PhD, MBA, CIH, College of Public Health, Department of Environmental, Agricultural, and Occupational Health, University of Nebraska Medical Center, Omaha, NE
John-Martin Lowe, PhD, MS, College of Public Health, Department of Environmental, Agricultural, and Occupational Health, University of Nebraska Medical Center, Omaha, NE
Introduction: Following the first case of confirmed Ebola virus disease (EVD) in the United States and the subsequent infection of two health care workers in Dallas, Texas, the Centers for Disease Control and Prevention (CDC) established a framework of hospitals ready to provide care for EVD patient care in the U.S. As of April 2015, 55 hospitals had been designated as Ebola Treatment Centers (ETC) possessing advanced capabilities in 11 areas set forth by the CDC. The CDC assessed each ETC on ability to adequately provide the complex care needed for EVD patients while effectively minimizing the risk of exposure to healthcare workers. The main objective of the study was to assess the structural and functional capabilities of the current Regional ETC centers.

Methods: In March 2015, a pilot survey was distributed to all 55 ETCs to inventory the current capacity of these facilities. The 19-question survey assessed the general structure of ETCs, including high-level isolation capacity and layout, infrastructure features for infection control, laboratory capabilities, and costs of establishing the ETC, and determined those ETCs applying to be the regional center.

Results: We present the findings here of the facilities applying to be a regional ETC center.

Discussion: We will use this information as a baseline measurement of the status of the current structural and functional capabilities of the regional ETC centers in the United States for caring for patients with EVD or other highly infectious diseases.

Learning Areas:

Administration, management, leadership
Clinical medicine applied in public health
Other professions or practice related to public health
Protection of the public in relation to communicable diseases including prevention or control
Public health or related research

Learning Objectives:
Describe current capabilities of Regional Ebola Treatment Centers Describe U.S. preparedness capabilities for Ebola Virus Disease Describe the U.S. response to the 2014-2015 Ebola Virus Disease outbreak in Africa Compare capabilities between Regional Ebola Treatment Centers Evaluate the expenses of developing the capabilities necessary to become an Ebola Treatment Center

Keyword(s): Emergency Preparedness, Hospitals

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I co-developed and distributed the initial Ebola Treatment Center Inventory of Capabilities survey to all 55 U.S. Ebola Treatment Centers. I am a Graduate Assistant with the Nebraska Biocontainment Unit. I evaluated the data received by the participating Ebola Treatment Centers.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 3192.0: Delta Omega Poster Session I